American Association for Cancer Research
Browse
15417786mcr160234-sup-166995_1_supp_3744950_1gpql1.xlsx (53.4 kB)

Supplemental Table 2 from A Genome-Wide Loss-of-Function Screen Identifies SLC26A2 as a Novel Mediator of TRAIL Resistance

Download (53.4 kB)
dataset
posted on 2023-04-03, 16:25 authored by Lina Y. Dimberg, Christina G. Towers, Kian Behbakht, Taylor J. Hotz, Jihye Kim, Susan Fosmire, Christopher C. Porter, Aik-Choon Tan, Andrew Thorburn, Heide L. Ford

Supplemental Table 2: GSEA analysis for upregualted (enriched) pathways in TRAIL treated BJAB-LEXR vs. BJAB WT

Funding

NIH

Department of Defense

Swedish Research Council

DOD

Bioscience Discovery and Evaluation

History

ARTICLE ABSTRACT

TRAIL is a potent death-inducing ligand that mediates apoptosis through the extrinsic pathway and serves as an important endogenous tumor suppressor mechanism. Because tumor cells are often killed by TRAIL and normal cells are not, drugs that activate the TRAIL pathway have been thought to have potential clinical value. However, to date, most TRAIL-related clinical trials have largely failed due to the tumor cells having intrinsic or acquired resistance to TRAIL-induced apoptosis. Previous studies to identify resistance mechanisms have focused on targeted analysis of the canonical apoptosis pathway and other known regulators of TRAIL receptor signaling. To identify novel mechanisms of TRAIL resistance in an unbiased way, we performed a genome-wide shRNA screen for genes that regulate TRAIL sensitivity in sublines that had been selected for acquired TRAIL resistance. This screen identified previously unknown mediators of TRAIL resistance including angiotensin II receptor 2, Crk-like protein, T-Box Transcription Factor 2, and solute carrier family 26 member 2 (SLC26A2). SLC26A2 downregulates the TRAIL receptors, DR4 and DR5, and this downregulation is associated with resistance to TRAIL. Its expression is high in numerous tumor types compared with normal cells, and in breast cancer, SLC26A2 is associated with a significant decrease in relapse-free survival.Implication: Our results shed light on novel resistance mechanisms that could affect the efficacy of TRAIL agonist therapies and highlight the possibility of using these proteins as biomarkers to identify TRAIL-resistant tumors, or as potential therapeutic targets in combination with TRAIL. Mol Cancer Res; 15(4); 382–94. ©2017 AACR.